Skip to main content
Rafael Holdings, Inc. logo

Rafael Holdings, Inc. — Investor Relations & Filings

Ticker · RFL ISIN · US75062C1009 US Professional, scientific and technical activities
Open in API
Filings indexed 393 across all filing types
Latest filing 2021-09-29 Director's Dealing
Country US United States of America
Listing US RFL

About Rafael Holdings, Inc.

https://rafaelholdings.com

Rafael Holdings, Inc. is a clinical-stage biotechnology company that invests in and develops therapies for difficult-to-treat diseases. The company holds interests in early-stage and clinical pharmaceutical entities, with a primary focus on novel cancer therapeutics aimed at improving and extending the lives of patients. Following a merger with Cyclo Therapeutics, Rafael Holdings is also advancing a potential breakthrough treatment for Niemann-Pick Type C1, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2021-09-29 English
FORM 4 SUBMISSION
Director's Dealing
2021-09-24 English
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the departure of a director/officer (Menachem Ash resigning as President and General Counsel) and the appointment of transition support. This matches the description of Board/Management Information filings, which announce changes in the company's board of directors or senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other type. It is also not a report publication announcement or certification. Therefore, the correct classification is MANG (Board/Management Information). The document length is under 5,000 characters, but it contains substantive information about management changes, not just an announcement of a report publication.
2021-09-24 English
FORM 4 SUBMISSION
Director's Dealing
2021-09-20 English
FORM 3 SUBMISSION
Director's Dealing
2021-09-17 English
REGISTRATION STATEMENT
M&A Activity Classification · 100% confidence The document is a Form S-4 Registration Statement filed with the SEC, dated September 14, 2021. It relates to a business combination (merger) between Rafael Holdings, Inc. and Rafael Pharmaceuticals, Inc. The text includes detailed information about the merger agreement, issuance of shares, proxy solicitation for a special meeting to approve the merger, and related transactions. The document is a regulatory filing required for securities registration in connection with a merger transaction. It is not an annual report, earnings release, or proxy statement alone, but a registration statement under the Securities Act of 1933. The Form S-4 is specifically used for merger and acquisition related securities registration. Therefore, the document fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2021-09-14 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.